Global Erythropoietin (EPO) Drugs Market – Industry Trends and Forecast to 2031

Global Erythropoietin (EPO) Drugs Market, By Drug Type (Biologics, and Biosimilars), Drugs (Epoetin-Alfa, Darbepoetin-Alfa, Epoetin-Beta, and Others), Indication (Cancer, Neurology, Hematology, Renal diseases, and Others), End-Users (Hospitals, Homecare, Speciality Centres, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy) – Industry Trends and Forecast to 2031.

Erythropoietin (EPO) Drugs Market Analysis and Size

The erythropoietin (EPO) drugs market witnesses high demand due to its crucial role in treating anemia associated with chronic kidney disease and cancer chemotherapy. EPO drugs stimulate red blood cell production, enhancing oxygen delivery. This aids in managing fatigue, improving quality of life, and reducing the need for blood transfusions, thus offering significant therapeutic benefits.

According to the CDC, over 37 million individuals in the U.S. experienced chronic kidney disease (CKD) in 2021. CKD leads to diminished red blood cell production, causing anemia. The increasing prevalence of CKD is anticipated to drive demand for erythropoietin drugs in the foreseeable future, addressing the needs of those affected and underscoring the importance of treatments for related conditions.           

Data Bridge Market Research analyses that the global erythropoietin (EPO) drugs market size was valued at USD 8.15 billion in 2023, is projected to reach USD 20.19 billion by 2031, with a CAGR of 12% during the forecast period 2024 to 2031. This indicates that the market value. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Erythropoietin (EPO) Drugs Market Scope and Segmentation

Market Definition

Erythropoietin (EPO) drugs are synthetic versions of a hormone naturally produced by the kidneys to stimulate red blood cell production in bone marrow. They are used medically to treat anemia associated with chronic kidney disease, cancer chemotherapy, and other conditions affecting red blood cell levels.           

Erythropoietin (EPO) Drugs Market Dynamics

Drivers

• Increasing Prevalence of Anemia

Rising anemia prevalence, attributed to conditions such as chronic kidney disease and cancer, propels the demand for erythropoietin drugs. These medications for anemia, targeting red blood cell deficiency, address a critical need in healthcare. As anemia cases surge, particularly among aging populations, the market for EPO drugs continues to expand, driven by the imperative to treat underlying conditions effectively.

• Government Initiatives for Enhanced Patient Affordability

Government initiatives promoting access to essential medicines and favorable reimbursement policies for erythropoietin therapy are pivotal in driving market growth. Through mitigating financial barriers to treatment, these measures enhance patient affordability and spur demand for erythropoietin drugs, consequently facilitating market expansion and improving healthcare accessibility, while driving the market.

Opportunities

• Advancements in Biotechnology for Patient Convenience

Biotechnological advancements drive the creation of advanced erythropoietin drugs boasting superior efficacy, safety, and patient convenience. These innovations meet unmet medical needs and broaden treatment options, stimulating market growth. Improved formulations cater to diverse patient populations, enhancing therapeutic outcomes and expanding accessibility to effective anemia management.

• Rising Healthcare Expenditure for Efficient Medication

Rising global healthcare spending, propelled by economic growth, expanded coverage, and technological advances, facilitates increased adoption of erythropoietin drugs. This trend is particularly notable in regions witnessing enhancements in healthcare infrastructure, indicating a growing demand for these medications to address conditions such as anemia associated with various chronic diseases. 

Restraints/Challenges

• Rising Concern about Side Effects

Erythropoietin side effects include risks of thromboembolic events, hypertension, and pure red cell aplasia (PRCA). These safety concerns prompt rigorous monitoring and label warnings, influencing how physicians prescribe, and patients accept the treatment. Stringent monitoring requirements aim to mitigate risks associated with EPO therapy, ensuring patient safety and informed decision-making. 

• Challenges in Clinical Trial

Clinical trials for EPO drugs are challenging due to the necessity for large patient cohorts, extended follow-up periods, and rigorous safety oversight. Meeting regulatory demands for efficacy and safety escalates the intricacy and expenses of drug development. These obstacles necessitate meticulous planning and resources to ensure successful trial execution and eventual market approval. 

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In November 2022, Dong-A ST and Polifarma inked a strategic agreement for the DA-3880 NESP biosimilar. Polifarma gained commercialization and development rights for DA-3880 in Brazil, Mexico, and Turkey
• In July 2020, PT Kalbe Genexine Biologics initiated a Phase III clinical trial of Efepoetin Alfa for treating anemia in chronic kidney disease patients not undergoing dialysis
• In February 2020, Samsung Medical Center launched a Phase III clinical trial investigating the efficacy of intravenous iron injection, Ferinject, in anemic cancer patients, conducting a multicenter randomized study

Global Erythropoietin (EPO) Drugs Market Scope

The market is segmented on the basis of drug type, indication, drugs, distribution channel, and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Type

• Biologics
• Biosimilars

 Drugs

• Epoetin-Alfa
• Darbepoetin-Alfa
• Epoetin-Beta
• Others

 Indication

• Cancer
• Neurology
• Hematology
• Renal diseases
• Others

 End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

 Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Erythropoietin (EPO) Drugs Market Regional Analysis/Insights

The market is analysed and market size insights and trends are provided by country, drug type, indication, drugs, distribution channel, and end-user as referenced above.

The countries covered in the market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America.

Asia-Pacific is expected to dominate the market, fueled by rising cardiovascular ailments and a swiftly aging demographic. The region's growing demand for EPO treatments underscores its pivotal role in addressing healthcare needs and advancing medical solutions.

North America has been witnessing growth in the market, attributed to increasing cancer prevalence and advanced healthcare facilities. This trend underscores the region's pivotal role in driving the global expansion of EPO drug usage.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Global Erythropoietin (EPO) Drugs Market Share Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.

Some of the major players operating in the market are:

• Pfizer Inc (U.S.)
• AstraZeneca (U.K.)
•  Bristol-Myers Squibb Company (U.S.)
•  Dr. Reddy's Laboratories Ltd (India)
•  Endo International plc (Ireland)
•  Teva Pharmaceutical Industries Ltd (Israel)
•  Sun Pharmaceutical Industries Ltd (India)
• Mylan N.V. (U.S.)
• Novartis AG (Switzerland)
•  Lupin (India)
• Cipla Inc (India)
•  Shanghai Dahua Pharmaceutical Co., Ltd (China)
•  JCR Pharmaceuticals Co., Ltd (Japan)